Janssen Submits Type II Extension Of Indication Application To EMA For Approval Of RYVREVANT, In Combination With Lazertinib, For First-Line Treatment Of Patients With EGFR-Mutated Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Janssen, a subsidiary of Johnson & Johnson (JNJ), has submitted a Type II extension of indication application to the European Medicines Agency (EMA) for the approval of RYVREVANT in combination with Lazertinib for the first-line treatment of patients with EGFR-mutated non-small cell lung cancer.
February 08, 2024 | 4:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's subsidiary Janssen has applied for EMA approval of RYVREVANT with Lazertinib for treating EGFR-mutated non-small cell lung cancer.
The submission for EMA approval of RYVREVANT in combination with Lazertinib by Janssen could significantly impact JNJ's market position in oncology treatments, especially if approved. This move indicates JNJ's commitment to expanding its portfolio in cancer therapy, potentially leading to increased investor confidence and a positive short-term impact on JNJ's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90